How do I find FDA warning letters for a compounding pharmacy?

How do I find FDA warning letters for a compounding pharmacy?

Search FDA’s warning letter database for the pharmacy’s legal name, any “dba” name and its city, then check FDA’s compounding inspections and actions page, which lists 111 warning letters to 105 compounding facilities along with Form 483s and close-out letters (current as of Oct 22, 2026). In this index, 9 GLP-1 warning letters went to compounding pharmacies or outsourcing facilities, the latest dated Sep 18, 2026 to Empower Clinic Services, LLC dba Empower Pharmacy.

Steps

  1. FDA’s warning letter database: search the legal name and the “dba” name separately. FDA’s subject line for compounders usually reads “Compounding Pharmacy/Adulterated Drug Products” or names CGMP.
  2. FDA’s compounding inspections and actions list: the pharmacy’s entry links each warning letter, close-out letter and Form 483 FDA has posted since 2019. FDA keeps earlier actions in an archive.
  3. Check for a close-out letter: it means FDA completed its review of the firm’s corrective actions.

Warning letters to compounders since 2025 on FDA’s actions list

Letter
Sep 18, 2026Empower Clinic Services, LLC, (dba Empower Pharmacy)Houston, TX503Afda.gov
Apr 7, 2026ProRX LLCExton, PA503Bfda.gov
Mar 20, 2026RC Outsourcing LLCLowellville, OH503Bfda.gov
Feb 9, 2026Thrive Health and Wellness, LLC, dba Thrive Health SolutionsEnglewood, CO503Afda.gov
Feb 2, 2026Apollo Care LLCColumbia, MO503Bfda.gov
Jan 20, 2026GenoGenix, LLCBoca Raton, FL503Bfda.gov
Jan 16, 2026Boothwyn Pharmacy LLCKennett Square, PA503Afda.gov
Dec 12, 2025MedisourceRxLos Alamitos, CA503Bfda.gov
Dec 1, 2025Apothecary Pharma LLCCary, NC503Bfda.gov
Nov 7, 2025Wells Pharma of Houston LLCHouston, TX503Bfda.gov
Oct 10, 2025PQ Pharmacy, LLCBrooksville, FL503Bfda.gov
Sep 22, 2025Revive RX LLC, dba Revive RX PharmacyHouston, TX503Afda.gov
Sep 16, 2025Turbare ManufacturingConway, AR503Bfda.gov
Jul 2, 2025Exela Pharma Sciences, LLCLenoir, NC503Bfda.gov
May 5, 2025Staska Pharmaceuticals, Inc.Bennet, NE503Bfda.gov
Apr 23, 2025OSRX, Inc.Missoula, MT503Bfda.gov
Apr 8, 2025Tailstorm Health, Inc.Phoenix, AZ503Bfda.gov
Apr 2, 2025Empower Clinic Services, LLC, (dba Empower Pharmacy)Houston, TX503BFDA copy (archived)
Apr 2, 2025Empower Clinic Services, LLC, (dba Empower Pharmacy)Houston, TX503Afda.gov
Mar 5, 2025Annovex Pharma, Inc.Lorton, VA503Bfda.gov
Mar 4, 2025ProRX LLCExton, PA503BFDA copy (archived)
Jan 22, 2025Nubratori Inc. dba Nubratori RxTorrance, CA503BFDA copy (archived)

GLP-1 warning letters to compounding pharmacies and outsourcing facilities

Later letters FDA listsLetter
Sep 18, 2026Empower Clinic Services, LLC dba Empower PharmacyCGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Apr 7, 2026ProRx LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Feb 9, 2026Thrive Health and Wellness, LLC dba Thrive Health SolutionsCompounding Pharmacy/Adulterated Drug ProductsTirzepatideClose-out letter, Aug 6, 2026fda.gov
Jan 20, 2026GenoGenix LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Jan 16, 2026Boothwyn Pharmacy, LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Dec 1, 2025Apothecary Pharma, LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Oct 10, 2025PQ Pharmacy, LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutideNone listed by FDA as of Nov 15, 2026fda.gov
Apr 8, 2025Tailstorm Health Inc. dba Medivant HealthCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideClose-out letter, Apr 14, 2026fda.gov
Mar 4, 2025ProRx, LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

Common questions

What is the difference between a warning letter and a Form 483?

A Form 483 lists conditions FDA investigators observed at the end of an inspection and is not a final agency determination. A warning letter is FDA’s formal notice of what it considers significant violations, and asks the firm to respond.

Where are warning letters older than 2019?

FDA’s compounding actions page links an archived version for actions before 2019, and the warning letter database itself can be searched by date range.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.